These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34053342)

  • 21. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
    Burdick BV; Adinoff B
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
    Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
    Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
    McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
    J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinding and expectancy confounds in psychedelic randomized controlled trials.
    Muthukumaraswamy SD; Forsyth A; Lumley T
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1133-1152. PubMed ID: 34038314
    [No Abstract]   [Full Text] [Related]  

  • 34. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The varieties of psychedelic law.
    Marks M
    Neuropharmacology; 2023 Mar; 226():109399. PubMed ID: 36565855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.
    Breeksema JJ; Niemeijer AR; Krediet E; Vermetten E; Schoevers RA
    CNS Drugs; 2020 Sep; 34(9):925-946. PubMed ID: 32803732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.